Evaluation on the Effectiveness and Safety of RuiXin-CoronaryAI for Diagnosis of Coronary Artery Stenosis

Last updated: September 19, 2022
Sponsor: Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Vascular Diseases

Cardiac Disease

Heart Disease

Treatment

N/A

Clinical Study ID

NCT05320185
RuiXin-CoronaryAI
  • Ages > 18
  • All Genders

Study Summary

With the emergence of advanced technology to date in the artificial intelligence (AI), computer aided diagnosis has gradually gained its popularity in the field of healthcare. Particularly, in the clinical practice of coronary artery disease diagnosis, the application of AI could be of great implication in alleviating the shortage of medical sources. To evaluate the effectiveness and safety of the AI-based coronary CT angiographic analysis software (RuiXin-CoronaryAI) for diagnosis of coronary artery stenosis, a retrospective, multi-center, cross-over designed, blinded, sensitivity superiority and specificity non-inferiority clinical trial will be conducted.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. layer thickness of CCTA images should be less than 1mm, image quality should be up toDICOM 3.0 standards;
  2. vessels should be clearly developed, contrast medium ought to be well filled, theaverage of CT value of aortic root cavity should be between 325-600HU in CCTA image;
  3. remodeling of vessels should be intact, including coronary artery and branches,without missed or inaccurate slices;
  4. CCTA image should be obtained from single- or dual-source computed tomography (CT)scanners with a minimum of 64 detector rows.

Exclusion

Exclusion Criteria:

  1. CCTA image is of poor quality due to motion artifact, severe calcification, metalcoverage, noise, poor contrast medium injection and other variables influencing thediagnosis of stenosis;
  2. previous percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG);
  3. anomalous origin of coronary artery;
  4. other non-atherosclerosis-related coronary diseases like coronary artery fistula,aneurysm, coronary artery ectasia, arteritis coronaria, etc.;
  5. repeated enrollment;
  6. other conditions not suitable for enrollment.

Study Design

Total Participants: 615
Study Start date:
July 28, 2021
Estimated Completion Date:
December 30, 2022

Study Description

Patients ≥18 years old with suspected or known coronary artery disease who underwent CCTA will be included. CCTA images of subjects should be of good quality up to the DICOM 3.0 standards, obtained by CT scan with ≥64-slices. The subjects with unqualified CTA will be excluded. CCTA images will be analyzed in three methods (3 groups). Control group: CCTA images will be visually evaluated by physicians. Experiment group: CCTA images will be evaluated by physicians using RuiXin-CoronaryAI. Reference group: CCTA images will be visually evaluated by cardiologists with at least 10 years experiences, and the conclusions they offer will be used as golden standard. Primary outcomes are diagnostic sensitivity and specificity of RuiXin-CoronaryAI and coronary CTA for diagnosis of ischemia on a per-vessel basis. The effectiveness of RuiXin-CoronaryAI for diagnosis of coronary artery stenosis will be conducted by testing superiority of diagnostic sensitivity and non-inferiority of specificity.

Connect with a study center

  • Beijing Hospital

    Beijing, Beijing 100730
    China

    Active - Recruiting

  • Sun Yat-sen Memorial Hospital

    Guangzhou, Guangdong 510120
    China

    Active - Recruiting

  • Tongji Hospital

    Wuhan, Hubei 430030
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.